Parkinson’s disease (PD) is the most common example of a family of neurodegenerative disorders characterized by a neuronal accumulation of the presynaptic protein alpha Synuclein. Parkinsonism is defined as paucity and slowness of movement (bradykinesia), tremor at rest, rigidity, shuffling gait and flexed posture. All forms of Parkinsonism result from a reduction of dopaminergic transmission within basal ganglia.

Parkinson’s Disease affects about 1 % of those above the age of 55 years. Its peak age of onset is in the 60s and the course of the illness ranges between 10 and 25 years.

Gross pathologic examination of the brain in PD reveals mild frontal atrophy with loss of the normal dark melanin pigment of midbrain. There is degeneration of the dopa minergic cells with the presence of Lewey Bodies (LBs) in the remaining neurons. LBs have high concentrations of alpha synuclein.

Indus is working on a novel molecule that targets selective Monoamine Oxidase (MAO)B inhibition.